265 related articles for article (PubMed ID: 21898479)
1. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients.
Myers RP; Pomier-Layrargues G; Kirsch R; Pollett A; Duarte-Rojo A; Wong D; Beaton M; Levstik M; Crotty P; Elkashab M
Hepatology; 2012 Jan; 55(1):199-208. PubMed ID: 21898479
[TBL] [Abstract][Full Text] [Related]
2. Deep attenuation transducer to measure liver stiffness in obese patients with liver disease.
Hirooka M; Koizumi Y; Nakamura Y; Yano R; Hirooka K; Morita M; Imai Y; Tokumoto Y; Abe M; Hiasa Y
J Med Ultrason (2001); 2023 Jan; 50(1):63-72. PubMed ID: 36525134
[TBL] [Abstract][Full Text] [Related]
3. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.
Chan WK; Nik Mustapha NR; Wong GL; Wong VW; Mahadeva S
United European Gastroenterol J; 2017 Feb; 5(1):76-85. PubMed ID: 28405325
[TBL] [Abstract][Full Text] [Related]
4. Liver Stiffness Values in Persons with Normal Histology.
Sharma D; Choudhary NS; Dhampalwar S; Saraf N; Duseja A; Gautam D; Soin AS; Sud R
J Clin Exp Hepatol; 2023; 13(1):10-14. PubMed ID: 36647399
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Elastography Point Quantification with Transient Elastography in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Disease: A Pilot Study.
Kapur S; Kalra N; Bhatia A; Duseja A; Das A; Dhiman RK; Chawla Y; Sandhu MS
J Clin Exp Hepatol; 2021; 11(1):21-29. PubMed ID: 33679045
[TBL] [Abstract][Full Text] [Related]
6. Applicability and variability of liver stiffness measurements according to probe position.
Ingiliz P; Chhay KP; Munteanu M; Lebray P; Ngo Y; Roulot D; Benhamou Y; Thabut D; Ratziu V; Poynard T
World J Gastroenterol; 2009 Jul; 15(27):3398-404. PubMed ID: 19610141
[TBL] [Abstract][Full Text] [Related]
7. The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study.
Curry MP; Tam E; Schneider C; Abdelgelil N; Hassanien T; Afdhal NH
Int J Hepatol; 2024; 2024():8877130. PubMed ID: 38274398
[TBL] [Abstract][Full Text] [Related]
8. Determining the ideal measurement site and respiratory condition for liver transient elastography: toward clinical practice standardization.
Huang Z; Lam SK; Cheng LK; Lin Y; Zheng Y
Insights Imaging; 2024 May; 15(1):114. PubMed ID: 38734997
[TBL] [Abstract][Full Text] [Related]
9. The application of high-performance ultrasound probes increases anatomic depiction in obese patients.
Heinitz S; Müller J; Jenderka KV; Schlögl H; Stumvoll M; Blüher M; Blank V; Karlas T
Sci Rep; 2023 Sep; 13(1):16297. PubMed ID: 37770538
[TBL] [Abstract][Full Text] [Related]
10. A mixture of experts model for the diagnosis of liver cirrhosis by measuring the liver stiffness.
Myoung S; Chang JH; Song K
Healthc Inform Res; 2012 Mar; 18(1):29-34. PubMed ID: 22509471
[TBL] [Abstract][Full Text] [Related]
11. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe.
Myers RP; Pomier-Layrargues G; Kirsch R; Pollett A; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
J Hepatol; 2012 Mar; 56(3):564-70. PubMed ID: 22027584
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.
Wong VW; Vergniol J; Wong GL; Foucher J; Chan AW; Chermak F; Choi PC; Merrouche W; Chu SH; Pesque S; Chan HL; de Lédinghen V
Am J Gastroenterol; 2012 Dec; 107(12):1862-71. PubMed ID: 23032979
[TBL] [Abstract][Full Text] [Related]
13. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
;
J Hepatol; 2015 Jul; 63(1):237-64. PubMed ID: 25911335
[No Abstract] [Full Text] [Related]
14. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®.
de Lédinghen V; Wong VW; Vergniol J; Wong GL; Foucher J; Chu SH; Le Bail B; Choi PC; Chermak F; Yiu KK; Merrouche W; Chan HL
J Hepatol; 2012 Apr; 56(4):833-9. PubMed ID: 22173167
[TBL] [Abstract][Full Text] [Related]
15. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.
Vuppalanchi R; Siddiqui MS; Van Natta ML; Hallinan E; Brandman D; Kowdley K; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Abdelmalek M; Doo E; Tonascia JA; Kleiner DE; Sanyal AJ; Chalasani N;
Hepatology; 2018 Jan; 67(1):134-144. PubMed ID: 28859228
[TBL] [Abstract][Full Text] [Related]
17. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
[TBL] [Abstract][Full Text] [Related]
18. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography].
Herrero JI; Iñarrairaegui M; D'Avola D; Sangro B; Prieto J; Quiroga J
Gastroenterol Hepatol; 2014 Apr; 37(4):233-9. PubMed ID: 24417906
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
